XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2

Note 12 - Segment Information (Tables)

6 Months Ended

Sep. 30, 2022

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

		Three Months Ended September 30,								Six Months Ended September 30,
		2022				2021				2022				2021
Revenues:
Clinical Genomics		$	18,435			$	-			$	32,940			$	-
Sterilization and Disinfection Control			16,964				14,033				31,738				29,183
Biopharmaceutical Development			12,144				10,555				23,111				19,432
Calibration Solutions			11,206				11,252				21,413				22,145
Total revenues (a)		$	58,749			$	35,840			$	109,202			$	70,760
Gross profit
Clinical Genomics		$	10,641			$	-			$	18,490			$	-
Sterilization and Disinfection Control			12,199				10,486				22,967				21,914
Biopharmaceutical Development			7,557				6,601				14,634				11,293
Calibration Solutions			6,007				6,128				11,671				12,240
Reportable segment gross profit			36,404				23,215				67,762				45,447
Corporate and Other (b)			(18	)			(75	)			(35	)			(96	)
Gross profit		$	36,386			$	23,140			$	67,727			$	45,351
Reconciling Items:
Operating expenses			32,391				18,939				68,326				38,027
Operating income (loss)			3,995				4,201				(599	)			7,324
Nonoperating expense (income), net			611				(342	)			1,429				1,363
Earnings (loss) before income taxes		$	3,384			$	4,543			$	(2,028	)		$	5,961

		September 30,				March 31,
		2022				2022
Clinical Genomics		$	12,600			$	11,802
Sterilization and Disinfection Control			2,864				2,176
Biopharmaceutical Development			5,214				4,495
Calibration Solutions			7,361				6,133
Total inventories		$	28,039			$	24,606

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_TableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration